Key result
Weight loss of ≥5% over 3 years prevented the decline in endothelial-dependent microvascular function compared to those with stable weight or weight gain.
Why the study?
Little is known about the progression of microvascular dysfunction in the early stages of type 2 diabetes before clinically apparent complications occur.
Does weight change or sulfonylurea therapy affect the progression of microvascular function over 3 years in people with and without type 2 diabetes?
Population
154 participants with type 2 diabetes and 99 without type 2 diabetes
Comparison
Participants with vs without type 2 diabetes, stratified by weight change and sulfonylurea use
Design
Prospective cohort study
Follow-up
3 years
Authors
Loading...
Weight gain and sulfonylurea use may accelerate microvascular decline in early type 2 diabetes; leaves open whether targeted interventions improve long-term outcomes.
Cohort (n=253)
No
Does weight change or sulfonylurea therapy affect the progression of microvascular function over 3 years in people with and without type 2 diabetes?
Absolute Event Rate: 1.2% vs -15.8%
p-value: p=<0.001
Physiological change in weight over 3 years is a major predictor of change in microvascular function, with weight loss protecting against decline, particularly in people with type 2 diabetes.
Casanova et al. (2020) conducted a cohort in Type 2 diabetes and healthy controls (n=253). Weight loss ≥5% vs. Stable weight was evaluated on Change in endothelial-dependent microvascular function (response to acetylcholine in AU × min) (p=<0.001). Weight loss of ≥5% over 3 years prevented the decline in endothelial-dependent microvascular function compared to those with stable weight or weight gain.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: